ID;Term;Depth;IC Nuno;IC zhou;IC sanchez;IC resnik;IC RZ;IC Rnormalized;IC Nuno org;Annotated Genes Set number
GO:0045806;negative regulation of endocytosis;7.0;0.7192862368539868;0.710562483684194;9.057979394024509;124.57926064357885;5.8650506222523235;0.004169555739685066;0.6508583268319309;[MCTP1, LGALS3, TGFB1, NR1H2, PRTN3, FCGR2B, EPHA3]
GO:0042538;hyperosmotic salinity response;5.0;0.8933024483968273;0.736892236059334;9.4949928598676;42.97243876554825;7.474488534686424;0.0014382488527988541;0.6724867031240476;[ABCB4, TACR3]
GO:0032693;negative regulation of interleukin-10 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.25422870398782;6.943860283624253;0.002184000309729388;0.6782296504172152;[PRG2, FCGR2B]
GO:0051491;positive regulation of filopodium assembly;9.0;1.0;0.896240625180289;9.628524252492122;200.30665838708023;6.409777797693995;0.006704083591926775;0.7240369598395108;[NLGN1]
GO:0008344;adult locomotory behavior;3.0;0.8436909121759173;0.6199657686781032;9.158520623246385;24.575257889458463;5.459585514144159;8.225117652639858E-4;0.47732376968016754;[CHL1, SCN1A, NR4A2]
GO:1902950;regulation of dendritic spine maintenance;7.0;0.8933024483968273;0.7975705894556142;9.427853557029971;39.538107659814585;7.474488534686424;0.0013233048813872785;0.7331650565203278;[FCGR2B]
GO:0002087;regulation of respiratory gaseous exchange by neurological system process;6.0;1.0;0.8231203125901445;9.628524252492122;40.361908422019745;7.212124270218933;0.0013508767515257331;0.6919486831672181;[NLGN1]
GO:0002244;hematopoietic progenitor cell differentiation;4.0;0.811012628672052;0.655506314336026;8.935377071932177;21.066225782797595;5.395046993006588;7.050676185779127E-4;0.5259029541176994;[TNFRSF13B, ESCO2, JAM3, TGFB1, INHBA]
GO:0007413;axonal fasciculation;7.0;0.8933024483968273;0.7975705894556142;9.446202695698167;31.514364772604104;6.7325511899570465;0.0010547574278521217;0.6952223462072524;[NCAM2, EPHA3]
GO:0001666;response to hypoxia;5.0;0.811012628672052;0.6957473261969462;9.117698628726131;21.16160540946;4.1860866471696125;7.082598888462125E-4;0.5043176776701113;[SLC8A1, MYB, AKT1, ACTN4, CLDN3, ABCB4, EGR1, TGFB1, NR4A2, NOX4, CD24, PTGS2]
GO:0048488;synaptic vesicle endocytosis;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;55.00680757199006;6.599019797332524;0.0018410283465216937;0.6605944919115335;[NLGN4Y, NLGN1]
GO:0001701;in utero embryonic development;7.0;1.0;0.8509193652572005;9.628524252492122;22.496195207419138;4.63541007117781;7.529274083310655E-4;0.5879744518658467;[MSH2, MAFF, PTPRR, HHEX]
GO:0071377;cellular response to glucagon stimulus;8.0;1.0;0.875;9.628524252492122;462.69925393661634;6.558197802812269;0.015486127626965131;0.7103865406232063;[ADCY9, PRKAR2B, ARG1, GLP2R]
GO:0007409;axonogenesis;8.0;0.6873818243518346;0.7186909121759173;8.667113085337498;64.60914726719044;4.956792062075433;0.0021624100145753813;0.6284905765689417;[STMN1, LINGO1, PTK2, NR4A2, OGN]
GO:0002638;negative regulation of immunoglobulin production;7.0;0.7980440201809971;0.7499413753476991;9.193206181234276;77.13462423321295;7.474488534686424;0.0025816264564307383;0.7331650565203278;[BCL6, FCRL3, FCGR2B]
GO:0019886;antigen processing and presentation of exogenous peptide antigen via MHC class II;5.0;1.0;0.7902410118609202;9.628524252492122;42.20009821028515;5.192106149009898;0.0014123993094755708;0.5557655617789146;[CTSS, HLA-DOA, HLA-DOB, AP2M1, DNM2, RACGAP1, HLA-DQA1, HLA-DRA, FCGR2B]
GO:0050710;negative regulation of cytokine secretion;9.0;0.6954798709641801;0.743980560662379;9.089527751759436;549.9868642983072;5.734022359845919;0.01840756539202174;0.6894787953221185;[IFNA2, NLRP3, IL1R2, NLRP12, BANK1, TLR8, FCGR2B]
GO:0046629;gamma-delta T cell activation;6.0;0.7866048967936545;0.7164227609869718;9.176539128749065;21.64461009501914;7.8311634786251565;7.244256209958813E-4;0.7236063770733796;[CXADR, CCR9, GPR18]
GO:1902564;negative regulation of neutrophil activation;7.0;0.9326813400603323;0.8172600352873667;9.5544162803384;126.92306413003195;8.390779266560578;0.00424800073309046;0.7800242071602487;[FCGR2B]
GO:1904861;excitatory synapse assembly;5.0;1.0;0.7902410118609202;9.628524252492122;37.238733880868345;8.16763571524637;0.0012463469103079984;0.7079342821725234;[NLGN1]
GO:0034220;ion transmembrane transport;5.0;0.44800904580126355;0.514245534761552;6.183841758890227;26.332710660334534;2.96803432163749;8.813321279004005E-4;0.4420264250971726;[AQP9, SCN1A, CACNA2D3, CLDN4, SLC22A4, GJC1, CLDN17, SGK1, STEAP4, DENND5B, SLC8A1, KCNE3, SLC26A8, KCNK5, ATP2A3, SLC40A1, SLC24A4, KCNJ15, P2RX5]
GO:0000902;cell morphogenesis;4.0;0.6260725219892441;0.563036260994622;7.923776160253697;43.26261951924051;4.420487353008457;0.0014479609414792109;0.47606392880653703;[CYFIP1, CDH3, CDH1, MEF2C, ACTN1, CLDN3, ST14, BCL11B, BCL6, NOX4, FLNA]
GO:0051260;protein homooligomerization;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;42.032160359171186;4.056761851073058;0.00140677858073304;0.5305833023127396;[CDA, TCL1A, OLFM4, CLDN3, BLM, MGST1, CD79B, CD79A, NACC2, CD3G, CD3E, ARG1, NUP54, ACPP, FBP1, NLGN1, NLRC4, SAMHD1, RAD51]
GO:0060999;positive regulation of dendritic spine development;11.0;0.9326813400603323;0.8987696223598284;9.596775554177542;671.848150157114;6.113511981550823;0.022486152961678982;0.7450742393735527;[NLGN1]
GO:0007268;chemical synaptic transmission;7.0;0.7369933605727446;0.7194160455435727;8.663443356448536;23.173347188538074;3.922001705478042;7.755910757418987E-4;0.5514907148670789;[NPY1R, GJC1, EGR3, PNOC]
GO:0008354;germ cell migration;5.0;0.9326813400603323;0.7565816818910864;9.510741216835738;40.540081573954176;7.57984905034425;0.0013568400465755524;0.6778748447945537;[TGFB1, CXADR]
GO:1900029;positive regulation of ruffle assembly;9.0;1.0;0.896240625180289;9.628524252492122;200.30665838708023;7.138016298065211;0.006704083591926775;0.7612791106150483;[CYFIP1, NLGN1, EPS8L1, PFN1]
GO:2000809;positive regulation of synaptic vesicle clustering;7.0;1.0;0.8509193652572005;9.628524252492122;59.688833127145365;8.16763571524637;0.001997731528303309;0.7686126355688037;[NLGN1]
GO:0006605;protein targeting;9.0;0.7192862368539868;0.7558837436072825;9.182237149863703;93.4429707305496;4.015022244900292;0.0031274521371376313;0.6015690495021188;[HGS, SLC27A2, NUP54, NLGN1]
GO:0002523;leukocyte migration involved in inflammatory response;6.0;0.9326813400603323;0.7894609826203107;9.510741216835738;29.137022145890857;7.379178354882098;9.751899096054872E-4;0.7004918368257019;[FFAR2, ELANE, S100A8, JAM3]
GO:0071480;cellular response to gamma radiation;7.0;1.0;0.8509193652572005;9.628524252492122;60.39874674087868;6.444869117505266;0.0020214916980741903;0.6805102716434839;[EGR1, CDKN1A, NOX4]
GO:0051893;regulation of focal adhesion assembly;7.0;0.8933024483968273;0.7975705894556142;9.474373572664863;59.47724087459839;5.769740442447999;0.0019906497260312257;0.6459841598043611;[ARHGAP6, PTK2, EPHA3]
GO:0032956;regulation of actin cytoskeleton organization;7.0;0.559792591703537;0.630815661108969;7.718981747607684;34.11626247365944;3.9689311377000256;0.0011418406023505395;0.553890688213353;[CYFIP1, CELSR1, CTGF, STMN1, MEF2C, PFN1, EPHA3, TACSTD2, CORO1A, STAP1, TGFB1, BST1, NOX4, ARHGEF10L, ARHGAP6, SPTAN1, RHOG, CIT, RHOU, LRP1, EPS8L1, FLNA, JAM3, GSN]
GO:0051496;positive regulation of stress fiber assembly;11.0;1.0;0.9324289523296623;9.628524252492122;365.07497849775285;5.926926025970411;0.012218730984170163;0.735532224928036;[ARHGEF10L, CTGF, NOX4]
GO:0002922;positive regulation of humoral immune response;6.0;0.6997970393407541;0.6730188322605215;9.0306872517365;108.8065326900253;7.069023426578259;0.0036416567296131998;0.6846304993685643;[FCER2, FCGR2B]
GO:0002924;negative regulation of humoral immune response mediated by circulating immunoglobulin;10.0;0.8933024483968273;0.861892236059334;9.592156608321247;508.9965303178644;7.9853141584524145;0.017035655802601874;0.8236103492792612;[CR1, FCGR2B]
GO:0048013;ephrin receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;31.002284443533863;5.395046993006588;0.0010376185600805164;0.6509029541176994;[AP2M1, MMP9, EPHA3, LYN, PTK2]
GO:0050966;detection of mechanical stimulus involved in sensory perception of pain;6.0;1.0;0.8231203125901445;9.628524252492122;71.50580126066325;7.379178354882098;0.0023932348171512878;0.7004918368257019;[SCN1A]
GO:0031103;axon regeneration;7.0;0.8436909121759173;0.7727648213451592;9.427853557029971;96.50678923292918;6.832634648514029;0.00322999538515464;0.7003406189322132;[CHL1, JAM3]
GO:0098904;regulation of AV node cell action potential;8.0;0.8259837884571596;0.7879918942285797;9.503361109538115;70.34216499897342;8.67846133901236;0.0023542889586771745;0.8188169164668168;[CXADR]
GO:0051897;positive regulation of protein kinase B signaling;8.0;1.0;0.875;9.628524252492122;238.41769229280743;4.7664383335842135;0.007979625599047746;0.6187558780415471;[FGF5, GAB1, CHI3L1, HBEGF, ENG, CD19, TGFB1, TRAT1, PTK2, NOX4]
GO:0007193;adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway;8.0;0.7866048967936545;0.7683024483968273;9.117698628726131;28.36322711391944;5.334422371190153;9.492916862557204E-4;0.6478026081386739;[NPY1R, FPR2, GNAI1, GNAI2, ADCY9, RGS1, FLNA]
GO:0043406;positive regulation of MAP kinase activity;12.0;0.7043150770688792;0.8002778511245842;9.369013057007038;2605.6877929993507;4.201124524534153;0.08721002546492271;0.6629660161470909;[, PROK2, MAP2K2, C5AR1, FPR1, IQGAP3, PDGFC, ELANE, TGFB1, GH1, NOX4, CD24, EZH2, LRRK2, MAP4K1, DUSP6, PKN1]
GO:0040014;regulation of multicellular organism growth;5.0;0.8933024483968273;0.736892236059334;9.377209824211215;36.77819272999274;5.557565922504363;0.0012309330124483187;0.5744551915910391;[PRL, NPY1R, GH1]
GO:0070507;regulation of microtubule cytoskeleton organization;7.0;0.6073376606709605;0.6545881955926808;8.242229891372231;33.71079736555127;4.584116776790259;0.0011282700500770656;0.5853513104054853;[STMN1, CHEK1, EPHA3, PLK2, XPO1, NUP62, CKAP2, SMC1A, PSRC1, GNAI1, RANBP1]
GO:0008285;negative regulation of cell proliferation;5.0;0.5619039856592722;0.5711930046905564;7.31175452450612;43.614270733588945;3.2818080717434612;0.0014597303911579066;0.4580728292695636;[MEF2C, SPINT1, BTK, SFN, LYN, BCL11B, CDC6, NOX4, CDKN1A, TNFRSF13B, PRL, PTPRK, BRCA2, DUSP1, ARG1, PAWR, CEACAM1, PTGS2, CDKN2C, PKN1, DACH1, TSC2, HGS, NACC2, IGFBP7, TGFB1, HMGA1, DHCR24, INHBA, BCL6, OGN, CXCL1, NUP62, E2F7, CD9, FCGR2B]
GO:0008284;positive regulation of cell proliferation;5.0;0.5587538620495764;0.5696179428857084;7.270369308343265;43.45254999490143;2.9881018846882994;0.0014543177435732513;0.44305268120482816;[PID1, MYB, AKT1, PROK2, MEF2C, CLDN7, ATF3, IQGAP3, PDGFC, ELANE, LYN, CDC6, CDKN1A, ARG1, FCRL3, MMP12, HBEGF, PTAFR, PTGS2, EPCAM, FLNA, LRG1, CTGF, FGF5, CDH3, MSH6, BLM, CORO1A, NACC2, BCL6, KLF5, TCL1A, SKP2, ICOSLG, RUNX2, EGR1, EGR3, PTK2, BST1, CD24, PRL, CD3E, RHOG, CEACAM6, GNAI2, CXCR2, CCNE1, PRTN3, C5AR1, LTBP3, TGFB1, NR4A1, HMGB2, LAMC2, GLP2R, MMP9, LTF, MEIS2, TSHR, CD4]
GO:0022900;electron transport chain;4.0;0.7140352122741334;0.6070176061370667;8.475844742553736;29.758801740447502;4.623782033182691;9.96000313069993E-4;0.48646042820481683;[POR, NOX4]
GO:0038096;Fc-gamma receptor signaling pathway involved in phagocytosis;10.0;1.0;0.9152410118609203;9.628524252492122;384.64074149301706;4.886724499458715;0.01287357946357817;0.6651483300191682;[CYFIP1, CD3G, IGHG1, FCGR3A, IGKC, IGLV1-44, LYN, PTK2, FCGR2A, FCGR2B, IGKV3-20]
GO:0043524;negative regulation of neuron apoptotic process;8.0;0.7866048967936545;0.7683024483968273;9.245532000236016;179.62959498689688;4.864418741944418;0.006012040888071555;0.6237666006816429;[CHL1, MEF2C, MSH2, LRP1, C5AR1, CORO1A, WFS1, NR4A2]
GO:0007628;adult walking behavior;4.0;1.0;0.75;9.628524252492122;34.938319875750295;6.518977089658987;0.0011693541237948906;0.5833807915285978;[SCN1A]
GO:0030889;negative regulation of B cell proliferation;9.0;1.0;0.896240625180289;9.628524252492122;506.3396801226706;7.004484905440688;0.016946733417578675;0.7544503089863854;[LYN, TNFRSF13B, PAWR, BTK, PKN1, FCGR2B]
GO:0071277;cellular response to calcium ion;6.0;1.0;0.8231203125901445;9.628524252492122;78.50383844342444;5.433268205826786;0.0026274528238337297;0.6009779013089371;[NLGN1, CPNE5, MEF2C, TUBG1]
GO:0097104;postsynaptic membrane assembly;5.0;1.0;0.7902410118609202;9.628524252492122;57.45028169597201;7.57984905034425;0.001922809226467428;0.6778748447945537;[NLGN4Y, NLGN1]
GO:0023041;neuronal signal transduction;5.0;1.0;0.7902410118609202;9.628524252492122;23.17027026302992;7.9853141584524145;7.75488093814194E-4;0.6986103492792611;[NLGN1]
GO:0097105;presynaptic membrane assembly;5.0;1.0;0.7902410118609202;9.628524252492122;57.45028169597201;7.474488534686424;0.001922809226467428;0.6724867031240476;[NLGN4Y, NLGN1]
GO:0010633;negative regulation of epithelial cell migration;8.0;0.7980440201809971;0.7740220100904985;9.427853557029971;243.45111910585655;5.602686357784832;0.008148089864690466;0.6615216408886768;[PTPRR, TACSTD2, MEF2C, TGFB1, JUP]
GO:0019227;neuronal action potential propagation;6.0;1.0;0.8231203125901445;9.628524252492122;26.361698197207048;7.8311634786251565;8.823023146724341E-4;0.7236063770733796;[SCN1A]
GO:0038128;ERBB2 signaling pathway;9.0;0.8653626801206646;0.8289219652406215;9.36615998802463;32.38857880465376;6.343086423195323;0.0010840165847632744;0.7206263598461826;[PTPRR, GAB1, HBEGF]
GO:0019226;transmission of nerve impulse;4.0;1.0;0.75;9.628524252492122;26.01624213687652;6.943860283624253;8.70740211223441E-4;0.6051093378270707;[JAM3]
GO:2000379;positive regulation of reactive oxygen species metabolic process;6.0;0.7763722522362496;0.7113064387082693;9.253830803050711;112.71770282919289;5.299736813202263;0.0037725600743465397;0.5941490996802742;[CDKN1A, PID1, ITGAM, AKT1, CD177, DNM2, FPR2, PTGS2, GNAI2, TGFB1, NOX4, PTX3]
GO:0048789;cytoskeletal matrix organization at active zone;6.0;1.0;0.8231203125901445;9.628524252492122;21.934314412845083;9.777073627680469;7.341217637965568E-4;0.8231203125901445;[NLGN1]
GO:1904646;cellular response to amyloid-beta;7.0;1.0;0.8509193652572005;9.628524252492122;273.93391051768003;6.518977089658987;0.009168321460513012;0.6843001567857983;[LRP1, FPR2, FCGR2B]
GO:0001780;neutrophil homeostasis;6.0;1.0;0.8231203125901445;9.628524252492122;41.67181410794555;8.16763571524637;0.0013947181159950893;0.7408135829017477;[JAM3]
GO:0001782;B cell homeostasis;7.0;0.9326813400603323;0.8172600352873667;9.510741216835738;22.00128503895464;6.599019797332524;7.363632103827933E-4;0.6883935445785896;[LYN, MEF2C, TNFRSF13B, PKN1]
GO:0097113;AMPA glutamate receptor clustering;9.0;1.0;0.896240625180289;9.628524252492122;45.884964450884205;8.390779266560578;0.0015357284663841083;0.8253454670833372;[NLGN1]
GO:0002622;regulation of B cell antigen processing and presentation;8.0;0.8933024483968273;0.8216512241984136;9.485423408851448;61.46352901150543;9.777073627680469;0.0020571290024302383;0.875;[FCGR2B]
GO:0097115;neurexin clustering involved in presynaptic membrane assembly;7.0;1.0;0.8509193652572005;9.628524252492122;44.498670089768545;9.777073627680469;0.001489330441701492;0.8509193652572005;[NLGN1]
GO:0097114;NMDA glutamate receptor clustering;8.0;1.0;0.875;9.628524252492122;45.884964450884205;8.390779266560578;0.0015357284663841083;0.8041048419030481;[NLGN1]
GO:0001811;negative regulation of type I hypersensitivity;11.0;1.0;0.9324289523296623;9.628524252492122;1110.322083208406;9.777073627680469;0.03716148089998564;0.9324289523296623;[FCGR2B]
GO:0071300;cellular response to retinoic acid;6.0;1.0;0.8231203125901445;9.628524252492122;200.602279209425;5.54296712308321;0.006713977754809188;0.606587909038952;[LYN, MYB, EPHA3]
GO:0042053;regulation of dopamine metabolic process;7.0;0.8259837884571596;0.7639112594857803;9.446202695698167;57.43424041378585;6.781341354126479;0.001922272339188874;0.6977174774718518;[NR4A2, ITGAM, TACR3]
GO:0016064;immunoglobulin mediated immune response;6.0;0.7586651285174919;0.7024528768488905;9.040737587590003;30.584352397600135;7.069023426578259;0.0010236307506175364;0.6846304993685643;[EXO1, TLR8, FCGR2B]
GO:0097119;postsynaptic density protein 95 clustering;6.0;1.0;0.8231203125901445;9.628524252492122;32.82490209968103;7.9853141584524145;0.0010986199327823658;0.7314896500084853;[NLGN1, LRRC4]
GO:0001814;negative regulation of antibody-dependent cellular cytotoxicity;13.0;1.0;0.9625549647676366;9.628524252492122;1597.8162410140733;9.777073627680469;0.05347747164548317;0.9625549647676366;[FCGR2B]
GO:0030593;neutrophil chemotaxis;9.0;1.0;0.896240625180289;9.628524252492122;130.2972973825895;5.382624473008031;0.004360933283440787;0.671508291047556;[CSF3R, C5AR1, CXCL1, CXCL2, LGALS3, CXCR1, CXCR2, CXADR, S100A8]
GO:0086072;AV node cell-bundle of His cell adhesion involved in cell communication;6.0;1.0;0.8231203125901445;9.628524252492122;24.262698198658363;9.777073627680469;8.120506736983656E-4;0.8231203125901445;[CXADR]
GO:0050900;leukocyte migration;5.0;0.6023560406934092;0.5914190322076249;8.01908634005802;26.939797568556347;3.896540641279769;9.016507803758389E-4;0.4895102814636384;[CSF3R, VPREB3, LGALS3, VPREB1, C3AR1, CD177, CXADR, PRTN3, S100A8, GYPA, C5AR1, FPR1, FPR2, CORO1A, NUP85, IGLV1-44, IGHA1, ELANE, LYN, TGFB1, AZU1, DEFA1, IGKV3-20, IGHM, ITGAM, CXCL1, CXCL2, TREM1, OLR1, FFAR2, MMP9, CEACAM1, CEACAM6, CXCR5, IGKC, CXCR1, EPCAM, CXCR2, JAM3, CD2, NLRP12]
GO:2001238;positive regulation of extrinsic apoptotic signaling pathway;9.0;0.8653626801206646;0.8289219652406215;9.54514264355307;358.11284317915005;5.8650506222523235;0.011985714580571521;0.6961795867550195;[PPP2R1A, G0S2, INHBA, PPP1CA, MAL, ATF3, ITM2C]
GO:2001199;negative regulation of dendritic cell differentiation;8.0;1.0;0.875;9.628524252492122;349.4674446787805;7.9853141584524145;0.01169636087311766;0.7833693374183408;[TMEM176B, TMEM176A, FCGR2B]
GO:2000302;positive regulation of synaptic vesicle exocytosis;11.0;0.8259837884571596;0.845420846558242;9.533214072687796;1061.769420372717;8.67846133901236;0.03553646696943479;0.8762458687964789;[NLGN1]
GO:0010460;positive regulation of heart rate;8.0;0.7763722522362496;0.7631861261181248;9.249034630787218;94.35920462208708;6.641579411751319;0.003158117660930423;0.7146506799819907;[TACR3]
GO:0018108;peptidyl-tyrosine phosphorylation;9.0;0.811012628672052;0.801746939516315;9.414950152194063;338.33129968976414;4.530049555519983;0.011323644122215096;0.627907570118429;[SLA2, FGF5, GRAP2, MAP2K2, MELK, BTK, EPHA3, BLK, CSF2RB, LYN, BMX, PTK2, HBEGF, WEE1]
GO:0090138;regulation of actin cytoskeleton organization by cell-cell adhesion;8.0;1.0;0.875;9.628524252492122;46.024468021678764;9.777073627680469;0.0015403975253535395;0.875;[JAM3]
GO:1902476;chloride transmembrane transport;8.0;1.0;0.875;9.628524252492122;110.5175749436453;5.311165509025885;0.0036989237740038075;0.6466132511260384;[CLDN4, SLC26A8, CLDN17]
GO:1900452;regulation of long term synaptic depression;8.0;0.8933024483968273;0.8216512241984136;9.446202695698167;41.65758488823441;7.212124270218933;0.0013942418768168238;0.7438283705770736;[SORCS3]
GO:1902474;positive regulation of protein localization to synapse;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;25.478761436601122;7.8311634786251565;8.527512158864491E-4;0.7236063770733796;[NLGN1]
GO:0008542;visual learning;8.0;1.0;0.875;9.628524252492122;51.65827414420079;5.970411137910149;0.00172895594617802;0.6803271032452366;[MEIS2, ADAM2]
GO:0006006;glucose metabolic process;6.0;0.7090535922965819;0.6776471087384355;8.572471578242808;34.676020684410545;5.040875179285974;0.0011605752059146955;0.5809109036834981;[HK3, AKT1, NPY1R, FBP1, ATF3]
GO:0051290;protein heterotetramerization;7.0;1.0;0.8509193652572005;9.628524252492122;85.45061507946225;6.444869117505266;0.002859955186148837;0.6805102716434839;[NLGN1, NUP54]
GO:0007217;tachykinin receptor signaling pathway;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;26.976932752798508;7.697632086000634;9.028936615729279E-4;0.7167775754447168;[TACR3]
GO:0060326;cell chemotaxis;5.0;0.6393367784920305;0.6099094011069355;8.152617732682543;30.286927728949156;4.458953633836253;0.0010136762146226118;0.5182721080578558;[CSF3R, LGALS3, C3AR1, CXADR, S100A8, C5AR1, FPR1, FPR2, CORO1A, NUP85, EGR3, AZU1, DEFA1, NR4A1, HMGB2, CXCL1, CXCL2, CCR9, FFAR2, RHOG, GAB1, HBEGF, CXCR5, CXCR1, CXCR2]
GO:0002316;follicular B cell differentiation;9.0;1.0;0.896240625180289;9.628524252492122;149.8071031872776;9.083926447120524;0.005013908926038414;0.8607930461318132;[FCGR2B]
GO:0043031;negative regulation of macrophage activation;7.0;0.9326813400603323;0.8172600352873667;9.5544162803384;126.92306413003195;7.57984905034425;0.00424800073309046;0.738553198190834;[BPI, FCGR2B, CD200]
GO:0071333;cellular response to glucose stimulus;8.0;1.0;0.875;9.628524252492122;272.3004295980195;5.69953618377475;0.009113650324169357;0.6664745454937787;[NOX4]
GO:0010977;negative regulation of neuron projection development;9.0;0.6763753087927167;0.7344282795766475;9.14017148457819;494.1264199049594;4.793467005972133;0.016537966589312465;0.6413787507847162;[LRRK2, TNR, NLGN1, LRP1, LINGO1, PLK2, PTK2, ITM2C]
GO:0002318;myeloid progenitor cell differentiation;5.0;1.0;0.7902410118609202;9.628524252492122;22.164838071467113;8.390779266560578;7.418371831928127E-4;0.7193458537639684;[JAM3]
GO:2000311;regulation of AMPA receptor activity;9.0;0.8933024483968273;0.8428918493787028;9.541512875502493;200.74624271324296;6.558197802812269;0.006718796083723233;0.7316271658034954;[MEF2C, NLGN1]
GO:2000310;regulation of NMDA receptor activity;9.0;0.8933024483968273;0.8428918493787028;9.541512875502493;200.74624271324296;6.8867018697843045;0.006718796083723233;0.7484268790654467;[MEF2C, NLGN1]
GO:0060291;long-term synaptic potentiation;8.0;1.0;0.875;9.628524252492122;145.7697243391103;5.948432231191374;0.004878781489395318;0.6792031009335148;[NLGN1, PLK2, TNR]
GO:0050911;detection of chemical stimulus involved in sensory perception of smell;5.0;1.0;0.7902410118609202;9.628524252492122;23.389107696328047;3.713288418992861;7.828123857657788E-4;0.48013875429378605;[OR11A1]
GO:0010976;positive regulation of neuron projection development;9.0;0.6763753087927167;0.7344282795766475;9.14017148457819;493.1928131726474;4.231896183200907;0.016506719612173492;0.6126599927924817;[CYFIP1, CPNE5, EPHA3, LYN, EZH2, NLGN1]
GO:0051968;positive regulation of synaptic transmission, glutamatergic;8.0;0.8933024483968273;0.8216512241984136;9.55953138100517;135.83014596643335;6.375876246018314;0.004546112746301595;0.701062607729944;[NLGN1, TNR, PTGS2]
GO:0019722;calcium-mediated signaling;7.0;0.7192862368539868;0.710562483684194;8.712233520617966;27.814661162170232;4.835431205071165;9.309316775279788E-4;0.598203541955087;[MCTP1, LRRK2, SLC8A1, CCR9, LAT2, BTK, CXCR5, FPR2, CXCR1, CXCR2, AZU1, LAT]
GO:0071219;cellular response to molecule of bacterial origin;5.0;0.7980440201809971;0.6892630219514189;9.253830803050711;59.34640842185874;4.720827822332161;0.001986270881579593;0.5316643662359317;[MEF2C, CD180, STAP1, NLRP3, DEFA4, DEFA1, HMGB2, CXCL1, CXCL2, CTSG, ARG1, TLR1, CEBPE, NR1H2, FCGR2B]
GO:0055007;cardiac muscle cell differentiation;6.0;0.7866048967936545;0.7164227609869718;9.0689084645567;45.916641199513585;6.409777797693995;0.0015367886586535107;0.6509166472493662;[MEF2C, NOX4, SIK1]
GO:0043318;negative regulation of cytotoxic T cell degranulation;11.0;1.0;0.9324289523296623;9.628524252492122;1135.3772244618756;9.083926447120524;0.03800005392957609;0.8969813732811862;[CEACAM1, FCGR2B]
GO:0061002;negative regulation of dendritic spine morphogenesis;12.0;1.0;0.9481203125901445;9.628524252492122;1979.5057838953023;7.9853141584524145;0.06625227714743111;0.8564896500084854;[NLGN1]
GO:0007186;G-protein coupled receptor signaling pathway;5.0;0.5508212674310002;0.5656516455764204;7.20077601654407;23.17027026302992;2.605416804911955;7.75488093814194E-4;0.4234821484283897;[C3AR1, AKT1, PROK2, TAS2R10, ADCY9, FPR1, FPR2, AZU1, PNOC, GPR18, CD3E, CCR9, FFAR2, RHOG, GPBAR1, TACR3, SORCS3, PTAFR, CXCR5, GNAI1, GNAI2, FGD4, CXCR1, CXCR2, FLNA, P2RY13, SORT1, CELSR1, RGS1, LHCGR, NPY1R, DGKZ, C5AR1, GPR84, GNB2, CXCL1, CXCL2, GLP2R, LRP1, TSHR, OR11A1]
GO:0030182;neuron differentiation;4.0;0.5833093054345528;0.5416546527172764;7.212610474191073;21.066225782797595;4.296434704338478;7.050676185779127E-4;0.4697198705845162;[MEF2C, RUNX2, JAG1, BCL11B, INHBA, NR4A2, ITM2C]
GO:0042220;response to cocaine;6.0;0.9326813400603323;0.7894609826203107;9.5544162803384;106.24722930474235;6.343086423195323;0.0035559991485312878;0.647506047256038;[TACR3, DNM2]
GO:0090022;regulation of neutrophil chemotaxis;10.0;0.8933024483968273;0.861892236059334;9.517298617381897;138.915002380433;6.193554689224359;0.004649360114287637;0.731979686697602;[C5AR1, CXCL1, CXCL2, BST1, CXCR2, C3AR1, JAM3]
GO:0007188;adenylate cyclase-modulating G-protein coupled receptor signaling pathway;7.0;0.7090535922965819;0.7054461614054914;8.712233520617966;27.67007993335845;4.535326612620827;9.260926739143067E-4;0.5828561791408859;[RGS1, LHCGR, GLP2R, NPY1R, ADCY9, FPR1, FPR2, GPR84, GNAI1, GNAI2, FLNA, TSHR]
GO:0007342;fusion of sperm to egg plasma membrane involved in single fertilization;6.0;1.0;0.8231203125901445;9.628524252492122;41.84633322739465;7.004484905440688;0.0014005591138660403;0.6813299963962409;[ADAM2, CD9, FOLR3]
GO:0043278;response to morphine;7.0;0.9326813400603323;0.8172600352873667;9.5544162803384;93.3430750065417;6.280566066213989;0.0031241087171554015;0.6721078059595746;[ABCB4, TACR3]
GO:0006898;receptor-mediated endocytosis;6.0;0.6799073451904818;0.6630739851853854;8.48339194818912;28.437470009997963;4.178651668682095;9.517765291732001E-4;0.536816753253722;[HP, AP2M1, FPR2, IGLV1-44, IGHA1, IGKV3-20, LRP12, DNM2, CEACAM1, LRP1, IGKC, CXCR1, CXCR2, CD9, FCGR2B]
GO:0042985;negative regulation of amyloid precursor protein biosynthetic process;9.0;1.0;0.896240625180289;9.628524252492122;967.9208223894049;7.9853141584524145;0.032395438853188026;0.8046099625986299;[ITM2C]
GO:0071560;cellular response to transforming growth factor beta stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;97.48528473772916;5.788089581116195;0.003262744749111514;0.6191234829421188;[MEF2C, TGFB1, ARG1, NOX4]
GO:0033209;tumor necrosis factor-mediated signaling pathway;7.0;0.8933024483968273;0.7975705894556142;9.510741216835738;30.19135422731818;5.395046993006588;0.00101047745553359;0.6268223193749;[TNFRSF13B, TNFRSF17, TNFRSF10C]
GO:0007218;neuropeptide signaling pathway;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;26.976932752798508;5.123113277522946;9.028936615729279E-4;0.5851165638517994;[SORT1, NPY1R, GPR84, SORCS3, PNOC, PROK2]
GO:0098942;retrograde trans-synaptic signaling by trans-synaptic protein complex;7.0;1.0;0.8509193652572005;9.628524252492122;46.63437644952677;9.777073627680469;0.0015608106115516636;0.8509193652572005;[NLGN1]
GO:0070474;positive regulation of uterine smooth muscle contraction;9.0;1.0;0.896240625180289;9.628524252492122;87.9006140514566;7.697632086000634;0.0029419544468855647;0.7898978880348613;[TACR3]
GO:0010628;positive regulation of gene expression;6.0;0.4705935272257725;0.5584170762030307;6.666693530613812;58.797024432214236;2.2471302570788807;0.001967883493859682;0.43803865843940215;[PID1, SPIB, AKT1, MEF2C, PADI2, ATF3, IQGAP3, JAG1, JUP, AZU1, MMP12, PTAFR, ATAD2, CTGF, BLM, FOXO1, CIITA, HHEX, E2F5, E2F7, POU2AF1, CCNH, EGR1, EGR2, EGR3, BRCA2, CD3E, CCNE1, HMGA1, INHBA, TCF4, HMGB2, ARHGEF10L, NUP62, PSRC1, CREB5, CD4, RAN, EHF, MYB, NUP85, NFE2, PAWR, PAX5, ENG, EPCAM, GSN, NR1H2, GTF2H1, CDH3, CDH1, MAP2K2, ADAM2, MAFF, RFC1, CEBPE, KLF5, CHEK1, EBF1, RUNX2, BEX1, BCL11B, IFNA2, PRL, RHOG, CAMK4, ARID4A, HGS, STAP1, NLRP3, TGFB1, NR4A2, NR4A1, SLC40A1, CKAP2, DNM2, MEIS2]
GO:0071320;cellular response to cAMP;7.0;1.0;0.8509193652572005;9.628524252492122;327.37290077043656;5.825829909099042;0.01095687637230394;0.6488525777373224;[PTAFR, AQP9, SLC8A1, NOX4]
GO:0002605;negative regulation of dendritic cell antigen processing and presentation;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;55.710237364246;9.083926447120524;0.0018645715086227877;0.7876727335416686;[FCGR2B]
GO:0032355;response to estradiol;5.0;0.9326813400603323;0.7565816818910864;9.523163736834295;74.25476231829794;4.940791720728991;0.0024852400698459885;0.542913330229313;[BRCA2, CTGF, DUSP1, TACR3, PCNA, ABCB4, PTGS2, RBBP8, TGFB1, GH1, CD4, EZH2]
GO:0050804;modulation of chemical synaptic transmission;6.0;0.5214636594213398;0.5838521423008144;7.2437010612611035;27.32355736088522;3.9162874042146036;9.144948752636959E-4;0.5233994325676684;[TNR, MEF2C, EGR2, PLK2, MCTP1, LRRK2, NRGN, SORCS3, NLGN1, RETN, PTGS2, GNAI1, GNAI2, NLGN4Y]
GO:0010469;regulation of signaling receptor activity;6.0;0.5916390046238794;0.6189398149020842;7.95454781892045;48.619731222684926;3.470798340732454;0.0016272586491059737;0.5006171011438312;[CTGF, FGF5, VSTM1, MEF2C, IFNA14, IFNA16, IFNA10, PDGFC, IFNA21, TGFB1, JAG1, INHBA, GH1, PNOC, OGN, IFNA5, IFNA4, IFNA7, IFNA2, CXCL1, PRL, IFNA8, CXCL2, HBEGF, NLGN1, RETN, CMTM2, FCGR2B]
GO:0086053;AV node cell to bundle of His cell communication by electrical coupling;5.0;1.0;0.7902410118609202;9.628524252492122;36.28951994211526;9.083926447120524;0.001214577574015016;0.7547934328124444;[GJC1]
GO:0050766;positive regulation of phagocytosis;8.0;0.7671156992804218;0.7585578496402109;9.34084218004034;175.32691305650852;5.825829909099042;0.005868033996023792;0.6729332124801218;[SIRPB1, STAP1, AZU1, DNM2, PTX3, FCGR2B]
GO:0050765;negative regulation of phagocytosis;8.0;0.8436909121759173;0.7968454560879586;9.503361109538115;175.4194889364855;7.069023426578259;0.005871132427413739;0.7365101867784198;[TGFB1, PRTN3, FCGR2B]
GO:0046718;viral entry into host cell;7.0;0.7671156992804218;0.7344772148974115;8.935377071932177;28.374411874040543;5.346256828837156;9.496660301113433E-4;0.6243271881103005;[ANPEP, CLEC5A, ITGB6, CR2, CR1, CXADR, GYPA]
GO:0032230;positive regulation of synaptic transmission, GABAergic;8.0;1.0;0.875;9.628524252492122;135.4246808583232;7.212124270218933;0.0045325421940280546;0.7438283705770736;[NLGN1]
GO:1905520;positive regulation of presynaptic active zone assembly;9.0;1.0;0.896240625180289;9.628524252492122;390.905034801094;9.777073627680469;0.013083239723101546;0.896240625180289;[NLGN1]
GO:1902533;positive regulation of intracellular signal transduction;7.0;0.5547065974044363;0.6282726639594187;7.95454781892045;189.47637744599322;2.856402123431786;0.006341603835448636;0.4969959026857851;[, AKT1, PROK2, ATF3, SEH1L, FPR1, FPR2, IQGAP3, PDGFC, ELANE, LYN, PLK2, NOX4, GPR18, EZH2, FCRL3, DUSP6, HBEGF, ENG, FLNA, PKN1, CTGF, FGF5, MAP2K2, S100A8, NACC2, CCDC22, LRRK2, NLGN1, P2RX5, FCGR2B, ACTN4, EPHA3, CD19, PTK2, CD24, IFNA2, PRL, CD3E, MAP4K1, GAB1, BANK1, TLR7, GNAI2, NLRP12, C5AR1, RASGRP4, TGFB1, GH1, NUP62, CHI3L1, LTF, TRAT1, CD4]
GO:0001570;vasculogenesis;4.0;0.8933024483968273;0.6966512241984136;9.292052015870908;21.066225782797595;5.6339389012889365;7.050676185779127E-4;0.5381198974168686;[GJC1, HHEX, TGFB1, PTK2, ENG]
GO:0048739;cardiac muscle fiber development;7.0;1.0;0.8509193652572005;9.628524252492122;104.2020218467692;7.004484905440688;0.003487547895480139;0.7091290490632969;[CXADR]
GO:0099054;presynapse assembly;4.0;1.0;0.75;9.628524252492122;34.5996765512564;7.474488534686424;0.0011580200364832854;0.6322456912631272;[NLGN4Y, NLGN1]
GO:0010717;regulation of epithelial to mesenchymal transition;5.0;0.7140352122741334;0.6472586179979869;8.999915593069748;54.42428208907013;5.395046993006588;0.001821531742847262;0.5661439659786197;[TGFB1, EPHA3, EZH2, ENG]
GO:0050771;negative regulation of axonogenesis;10.0;0.7436939687323844;0.7870879962271125;9.36383169826504;885.0968544383536;5.54296712308321;0.029623395182598163;0.6987086083097278;[TNR, LINGO1, PTK2]
GO:0006855;drug transmembrane transport;5.0;0.5781283279524737;0.5793051758371571;7.293149336675085;29.084245973375534;5.407625775213448;9.73423538606871E-4;0.5667872454856517;[ABCB4, SLC19A2, ABCA8]
GO:0043171;peptide catabolic process;6.0;0.7192862368539868;0.682763431017138;8.971744716103052;139.83704318034597;6.280566066213989;0.0046802199900778775;0.6443087532925187;[TRHDE, ANPEP]
GO:0009968;negative regulation of signal transduction;6.0;0.43649654099988644;0.5413685830900877;6.680044863788677;140.65047919891595;2.686163805600486;0.0047074449615745265;0.460490854527945;[, PID1, SLA2, STMN1, AKT1, UBASH3A, PADI2, ATF3, FIGNL1, LYN, EZH2, LRRC4, DUSP2, DUSP1, ARG1, FCRL3, PAWR, DUSP6, AES, MMP12, PTGS2, NR1H2, SULF2, TLE4, LY96, FOXO1, WFS1, BCL6, CCDC22, LRRK2, HHEX, LRP1, LGALS3, PPP2R1A, IL1R2, RUNX2, SIK1, EPHA3, EGR1, VNN1, PTPRR, CD3E, CEACAM1, BANK1, GNAI2, NLRP12, RGS1, TSC2, HGS, STAP1, NLRP3, TGFB1, NR4A2, HMGB2, NUP62, ARAP3, MMP9, DNM2, FBP1, LTF]
GO:0140058;neuron projection arborization;8.0;0.8436909121759173;0.7968454560879586;9.420884887713877;64.60914726719044;7.57984905034425;0.0021624100145753813;0.7626338329336335;[NLGN1, LRRK2]
GO:0034765;regulation of ion transmembrane transport;6.0;0.45556283921517005;0.5509017321977295;6.676594601596523;33.03735142972539;3.697140432584879;0.0011057304206669666;0.512192246247148;[, SLC8A1, AKT1, SCN1A, MEF2C, CACNA2D3, ACTN4, GEM, KCNE3, CORO1A, CD19, LYN, TGFB1, KCNK5, CTSS, MMP9, DNM2, NLGN1, PTAFR, FLNA, KCNJ15, TSPAN13]
GO:0033674;positive regulation of kinase activity;9.0;0.6073376606709605;0.6999094555157693;8.620883742029738;265.89784403492143;3.4106031799490317;0.008899361547325376;0.5706590304121504;[, CCNH, TCL1A, AKT1, PROK2, ACSL1, EPHA3, FPR1, FPR2, IQGAP3, PRKAR2B, PDGFC, ELANE, LYN, EGR1, CDC6, AZU1, PTK2, NOX4, CD24, EZH2, CDKN1A, MAP4K1, DUSP6, PKN1, MAP2K2, C5AR1, STAP1, TGFB1, GH1, LAT, LRRK2, PSRC1, CHI3L1, LTF, CD4]
GO:0014911;positive regulation of smooth muscle cell migration;8.0;0.8933024483968273;0.8216512241984136;9.510741216835738;201.77833622021802;6.280566066213989;0.0067533393245778365;0.6961884407023742;[DOCK5, NOX4]
GO:1902093;positive regulation of flagellated sperm motility;7.0;0.9326813400603323;0.8172600352873667;9.55953138100517;154.66121258067747;7.474488534686424;0.005176371599020676;0.7331650565203278;[TACR3]
GO:0035335;peptidyl-tyrosine dephosphorylation;8.0;0.8933024483968273;0.8216512241984136;9.52844079393514;179.24922260518233;5.181953777545879;0.005999310166768488;0.6400053571691908;[PTPRR, PTPRK, DUSP2, DUSP1, DUSP6]
GO:0086021;SA node cell to atrial cardiac muscle cell communication by electrical coupling;5.0;1.0;0.7902410118609202;9.628524252492122;36.28951994211526;9.083926447120524;0.001214577574015016;0.7547934328124444;[GJC1]
GO:2000573;positive regulation of DNA biosynthetic process;8.0;0.7980440201809971;0.7740220100904985;9.427853557029971;748.2879117532506;5.618190544320798;0.02504452299098255;0.6623145257091445;[RFC5, RFC3, RFC4, RFC2, NOX4]
GO:0031532;actin cytoskeleton reorganization;6.0;1.0;0.8231203125901445;9.628524252492122;32.01253927882412;5.788089581116195;0.001071430880247358;0.6191234829421188;[FLNA, CXADR, GAB1]
GO:0050776;regulation of immune response;4.0;0.37937792944451876;0.4396889647222594;5.635843344046521;22.446924158408432;2.846578861728843;7.512783506617425E-4;0.39557417536826767;[, CYFIP1, SLA2, MYB, C3AR1, UBASH3A, MEF2C, CXADR, FPR1, FPR2, IGHA1, HLA-DQA1, ELANE, LYN, SIGLEC9, ARG1, FCRL3, PAWR, PAX5, MMP12, FCER2, TLR10, PTAFR, UNG, NR1H2, PKN1, CLC, IGHG1, GRAP2, CD177, CD180, MSH6, CLEC4D, MSH2, S100A8, BLK, LY96, IGLV1-44, BMX, BCL6, HLA-DRA, LAT, ITGAM, TREM1, FCGR3A, CR2, CR1, UNC93B1, NLRC4, FCGR2A, FCGR2B, LGALS3, ICOSLG, BTK, STXBP2, CD1B, CD79B, CD79A, CD19, SH2D1A, PTK2, CD24, CD200, IGHM, IFNA2, CD3G, CD3E, CTSS, FFAR2, CTSG, LAT2, TLR1, CEACAM1, IGHD, TLR8, TLR7, TLR5, IGKC, MLH1, IL18RAP, OSCAR, CD300C, C5AR1, STAP1, NLRP3, TGFB1, IGKV3-20, HMGB2, LTF, SAMHD1, TRAT1, CD4]
GO:0035176;social behavior;3.0;1.0;0.6981203125901445;9.628524252492122;22.58175877758554;5.8067817141283475;7.557911440223213E-4;0.49507939949363344;[NLGN4Y]
GO:0007286;spermatid development;5.0;1.0;0.7902410118609202;9.628524252492122;72.7828096339012;5.370354380416217;0.0024359751381706407;0.5648811846224242;[JAM3]
GO:1903078;positive regulation of protein localization to plasma membrane;8.0;0.8436909121759173;0.7968454560879586;9.434368238051164;218.50214452761784;5.845247994956144;0.00731307013817619;0.6739262542938873;[LRP1, AKT1, RHOG, EPHA3]
GO:1900244;positive regulation of synaptic vesicle endocytosis;8.0;0.9326813400603323;0.8413406700301662;9.577230958104572;265.8961164942356;7.9853141584524145;0.008899303728093307;0.7833693374183408;[NLGN1, LRRK2]
GO:0001580;detection of chemical stimulus involved in sensory perception of bitter taste;6.0;1.0;0.8231203125901445;9.628524252492122;24.998545608763582;6.063501560976162;8.36678824294913E-4;0.6332080644001243;[TAS2R10]
GO:0007166;cell surface receptor signaling pathway;5.0;0.43360584258713153;0.507043933154486;5.906854975555195;23.17027026302992;2.006850423521684;7.75488093814194E-4;0.39287143584790796;[, SLA2, C3AR1, AKT1, MEF2C, FPR1, FPR2, PDGFC, LYN, JAG1, VANGL1, SIGLEC9, LRRC4, PTAFR, PTGS2, FLNA, P2RY13, NCF4, F13A1, CTGF, AP2M1, IFNA14, IFNA16, IFNA10, BLK, TACSTD2, LY96, CORO1A, FOXO1, TNFRSF17, IFNA21, TNFRSF10C, BMX, LCN2, HLA-DRA, CIITA, ITGAM, ITGB4, LRRK2, HHEX, FCGR3A, ITGB6, TSPAN13, FCGR2A, FCGR2B, BTK, EPHA3, CD19, TSPAN2, EGR1, PTK2, CD24, IGHM, PTPRR, TNFRSF13B, CD3G, PTPRK, CD3E, CCR9, CD37, GAB1, LAT2, IGHD, GNAI2, IGKC, SORT1, CELSR1, GEM, OSCAR, CCNE1, RASGRP4, INHBA, GH1, IGKV3-20, SIRPB1, NUP62, MMP9, SAMHD1, CD2, CD4, CD7, CD9, CDA, CYFIP1, STMN1, IGHA1, HLA-DQA1, CDK14, CDKN1A, AES, FCER2, HBEGF, ENG, ALOX5, G0S2, SULF2, ZYX, CSF3R, FGF5, IGHG1, CDH3, GRAP2, TLE4, CLEC4D, IGLV1-44, BCL6, LAT, CR2, CR1, P2RX5, ICOSLG, ACSL1, IL1R1, IL1R2, RUNX2, TLN1, PFN1, CD79B, CD79A, IFNA5, IFNA4, IFNA7, IFNA2, PRL, IFNA8, FFAR2, GPBAR1, CEACAM1, RHOU, CXCR5, CXCR1, CXCR2, KRT19, IL18RAP, TSC2, KIF16B, PRTN3, C5AR1, CSF2RB, STAP1, TGFB1, NR4A2, CXCL1, CXCL2, BLNK, GLP2R, REPS2, TRAT1, TSHR]
GO:0048468;cell development;3.0;0.5052934683962566;0.45076704678827284;6.510574346213882;28.41553699003407;3.2909128387363804;9.510424507334451E-4;0.36641774820622075;[AKT1, MEF2C, CXADR, RUNX2, ABCB4, GJC1, SFN, TSPAN2, LYN, JAG1, BCL11B, ENG, FLNA, JAM3, GSN, MLH1, SULF2, ARID4A, SLC8A1, CLEC5A, MSH2, S100A8, TGFB1, INHBA, BCL6, LSR, KLF5, CD9]
GO:1905898;positive regulation of response to endoplasmic reticulum stress;7.0;0.7763722522362496;0.7391054913753253;9.136047767394327;86.77986502582442;6.166155715036245;0.002904443985606294;0.6662568552797195;[FCGR2B, ATF3]
GO:0007569;cell aging;3.0;0.7980440201809971;0.597142322680643;8.935377071932177;24.751975343904395;5.618190544320798;8.284263394289076E-4;0.485434838299289;[CDKN1A, BRCA2, NUP62, CHEK1, MME, HMGA1, NOX4, ENG]
GO:1901216;positive regulation of neuron death;6.0;0.811012628672052;0.7286266269261705;9.260799472366804;58.38287487682085;5.370354380416217;0.001954022280951067;0.5977604853516485;[ITGAM, MYB, EGR1, FCGR2B, UBE2M]
GO:0007204;positive regulation of cytosolic calcium ion concentration;11.0;0.6835726970475526;0.7742153008534385;9.097896001429952;290.3013502407617;4.174954806800768;0.00971612493830514;0.645936335304707;[SLC8A1, C3AR1, PROK2, C5AR1, FPR1, FPR2, CD19, CD24, GPR18, CCR9, CD52, CXCR5, CXCR1, CXCR2, P2RX5, CD4]
GO:0097155;fasciculation of sensory neuron axon;8.0;1.0;0.875;9.628524252492122;32.20751195316447;8.67846133901236;0.0010779564401935146;0.8188169164668168;[EPHA3]
GO:0009617;response to bacterium;5.0;0.7508913569872202;0.6656866903545304;8.935377071932177;27.267803904038782;3.9481280100702625;9.126288572378991E-4;0.49214846190264216;[, HP, IGHG1, RNASE6, RNASE3, CHIT1, CLEC4D, SLPI, S100A8, SEH1L, C5AR1, NLRP3, IGHA1, ELANE, DEFA4, PRG2, AZU1, DEFA1, LYZ, IGKV3-20, IGHM, HMGB2, CTSG, CAMP, ANXA3, TLR1, IGHD, BPI, TLR5, LTF, CEBPE, HIST1H2BK, PTAFR, NLRC4, IGKC, CD4, FCGR2B]
GO:0097156;fasciculation of motor neuron axon;8.0;1.0;0.875;9.628524252492122;32.20751195316447;9.083926447120524;0.0010779564401935146;0.839552420951524;[EPHA3]
GO:0002305;CD8-positive, gamma-delta intraepithelial T cell differentiation;9.0;1.0;0.896240625180289;9.628524252492122;91.12402004725458;9.083926447120524;0.0030498389446878675;0.8607930461318132;[CCR9, GPR18]
GO:0070373;negative regulation of ERK1 and ERK2 cascade;11.0;1.0;0.9324289523296623;9.628524252492122;1180.902522994834;5.6339389012889365;0.039523744701365535;0.7205488497465309;[PTPRR, LYN, DUSP1, DUSP6, NLRP12, ATF3]
GO:0070098;chemokine-mediated signaling pathway;7.0;0.7307253602413294;0.7162820453778652;8.999915593069748;30.19135422731818;5.459585514144159;0.00101047745553359;0.6301228223472235;[CXCR5, CXCL1, CXCL2, CXCR1, CXCR2, CCR9]
GO:0046330;positive regulation of JNK cascade;12.0;0.8436909121759173;0.8699657686781033;9.567899630675686;1762.0380321839782;4.909539177224887;0.058973827205923174;0.6991943744303455;[CTGF, MAP4K1, PKN1, FCGR2B]
GO:0043066;negative regulation of apoptotic process;7.0;0.5640623033008358;0.6329505169076184;7.792313020693233;81.07407142393629;2.9735683700721314;0.0027134762086319553;0.5029877899877601;[AKT1, PROK2, MEF2C, CLDN7, FIGNL1, SFN, BARD1, PLK2, AZU1, CDKN1A, CHL1, DUSP1, ANXA5, PTGS2, UNG, FLNA, CLEC5A, MSH2, BLM, CORO1A, FOXO1, WFS1, TNFRSF10C, DHCR24, BCL6, LRRK2, ADAMTS20, LRP1, NLRC4, LGALS3, TCL1A, POR, EPHA3, EGR3, BCL11B, PTK2, VNN1, CEACAM6, GNAI2, CXCR2, C5AR1, CBX4, NR4A2, HMGB2, SLC40A1, NUP62, MMP9, LTF]
GO:0006508;proteolysis;5.0;0.5517781253862416;0.5661300745540411;7.338517941704937;47.85814540089318;2.5985281439167696;0.001601769057033345;0.42312986198474045;[, ELANE, BARD1, ST14, AZU1, OLR1, MMP12, FAM105A, ADAM28, APEH, IGHG1, RUVBL1, ADAM2, IGLV1-44, WFS1, DHCR24, ADAMTS20, RNF24, ANPEP, SKP2, CTSS, CTSG, MME, IGKC, RANBP1, PRTN3, TRHDE, NLRP3, TGFB1, IGKV3-20, MMP8, MMP9, LTF]
GO:0043065;positive regulation of apoptotic process;7.0;0.5587538620495764;0.6302962962819887;7.806911820114386;80.91235068524658;3.3969510907807043;0.0027080635610472266;0.5246396020141064;[MYB, AKT1, MEF2C, ATF3, SFN, BARD1, LYN, NOX4, DUSP1, PAWR, DUSP6, AES, PTGS2, FGD4, GSN, BIK, G0S2, CTGF, MELK, MAL, S100A8, FOXO1, NACC2, BCL6, NLRC4, PPP2R1A, SIK1, ITM2C, CXCR2, SORT1, PPP1CA, NLRP12, NLRP3, TGFB1, INHBA, UBE2M, MMP9, DNM2]
GO:0070374;positive regulation of ERK1 and ERK2 cascade;11.0;0.9326813400603323;0.8987696223598284;9.604993755081928;1178.864923326294;4.330336256014159;0.03945554807418015;0.6538825498434562;[CTGF, EPHA3, C5AR1, FPR2, PDGFC, TGFB1, NOX4, CHI3L1, GNAI2, CD4]
GO:0045088;regulation of innate immune response;6.0;0.4673148936341128;0.556777759407201;6.780712109014753;42.469229973879315;3.8881956693475885;0.0014214069074002054;0.52196281994017;[BTK, LYN, SH2D1A, CTSS, FFAR2, ARG1, FCRL3, MMP12, TLR1, CEACAM1, TLR8, TLR10, TLR7, TLR5, NR1H2, IL18RAP, CD180, CLEC4D, S100A8, LY96, ITGAM, HMGB2, CR1, LTF, UNC93B1, NLRC4, SAMHD1, FCGR2B]
GO:0010841;positive regulation of circadian sleep/wake cycle, wakefulness;6.0;1.0;0.8231203125901445;9.628524252492122;109.56266212983566;8.390779266560578;0.0036669637014913365;0.7522251544931926;[NLGN1]
GO:0016264;gap junction assembly;6.0;1.0;0.8231203125901445;9.628524252492122;56.140948375987016;7.8311634786251565;0.001878987018571015;0.7236063770733796;[GJC1]
GO:0034599;cellular response to oxidative stress;4.0;0.7248374789738407;0.6124187394869203;8.935377071932177;68.67201153720991;4.519578255652688;0.0022983904253524798;0.48113144217596127;[IL18RAP, MYB, AKT1, BTK, MGST1, FOXO1, NR4A2, NOX4, EZH2, LRRK2, PTPRK, ARG1, MMP9, DNM2, PCNA]
GO:2000463;positive regulation of excitatory postsynaptic potential;8.0;0.9326813400603323;0.8413406700301662;9.589303539338841;397.97278468673557;6.518977089658987;0.013319790951212034;0.7083807915285978;[NLGN1]
GO:0035725;sodium ion transmembrane transport;8.0;0.8933024483968273;0.8216512241984136;9.4949928598676;113.92400819162063;5.014899692882714;0.0038129340292226534;0.6314622035107071;[SLC24A4, SLC8A1, SCN1A]
GO:0050667;homocysteine metabolic process;8.0;0.8436909121759173;0.7968454560879586;9.456673995565463;188.66608657723927;7.292166977892469;0.006314484129285878;0.747921758369865;[NOX4]
